Cargando…
BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination
The proto-oncogene BCL-3 is upregulated in a subset of colorectal cancers (CRC), where it has been shown to enhance tumour cell survival. However, although increased expression correlates with poor patient prognosis, the role of BCL-3 in determining therapeutic response remains largely unknown. In t...
Autores principales: | Parker, Christopher, Chambers, Adam C., Flanagan, Dustin J., Ho, Jasmine Wing Yu, Collard, Tracey J., Ngo, Greg, Baird, Duncan M., Timms, Penny, Morgan, Rhys G., Sansom, Owen J., Williams, Ann C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618080/ https://www.ncbi.nlm.nih.gov/pubmed/35468497 http://dx.doi.org/10.1016/j.dnarep.2022.103331 |
Ejemplares similares
-
Aspirin reprogrammes colorectal cancer cell metabolism and sensitises to glutaminase inhibition
por: Holt, Amy K., et al.
Publicado: (2023) -
The role of B-Cell Lymphoma-3 (BCL-3) in enabling the hallmarks of cancer: implications for the treatment of colorectal carcinogenesis
por: Legge, Danny N, et al.
Publicado: (2020) -
Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007) -
Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas
por: Kelly, J D, et al.
Publicado: (2004) -
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
por: de Graaff, Marieke A, et al.
Publicado: (2016)